Particle Therapy 2017

Prostate:

RTOG-0938.

Phase II trial with hypofractionated RT

for favorable risk prostate cancer

. It

randomized between 7.25 Gy in 5 fractions versus 4.3 Gy in 12 fractions. Stage T1-T2 disease.

Study closed – reached accrual. Thus far, although protons were allowed, (almost) no proton

patients entered.

Currently, no specific concepts within RTOG’s prostate trials that would allow protons or are

proton specific..

Liver:

RTOG-1112

, open and permitting protons.

Randomized phase III study of Sorafenib alone versus SBRT followed by Sorafenib in

hepatocellular CA. Intention is to give 50 Gy in 5 fractions. Total dose prescription dependent on

the mean liver dose tolerance. Prescription dose to be lowered until a level that permits mean

liver dose OAR to be met. Open

NRG: